Cash PositionRallybio ended with $66M in cash, which provides runway into the second half of 2026.
Investor InterestPhase 1 data for differentiated C5 inhibitor RLYB116 could draw investor interest back to RLYB.
Pipeline DevelopmentRallybio will focus its resources on advancing other pipeline programs, notably RLYB116, an inhibitor of complement component 5 with potential applications in treating complement-related diseases.